← Back to Search

Monoclonal Antibodies

FLT PET for Malignant Melanoma (MPAK Trial)

Q: Is this experiment presently seeking participants?

Unfortunately, no more participants can be accepted for this trial. The study was published on October 1st 2015 and last updated April 8th 2022. For those seeking other trials, 758 studies involving <a href="https://www.withpower.com/clinical-trials/melanoma">melanoma</a> are presently enrolling patients while 960 FLT PET experiments require volunteers.

Q: What medical applications normally require the use of FLT PET imaging?

FLT PET is a commonly used therapy for various forms of <a href="https://www.withpower.com/clinical-trials/cancer">cancer</a>, such as <a href="https://www.withpower.com/clinical-trials/melanoma">melanoma</a> and tumors with microsatellite instability high. Additionally, it can be utilized to measure the effects of chemotherapy on disease progression.

Q: Has there been any previous experimentation involving FLT PET?

At present, the medical community is running 960 clinical trials to study FLT PET. Of those experiments, 122 are in Phase 3 of development. Although Houston, <a href="https://www.withpower.com/clinical-trials/texas">Texas</a> has the most studies surrounding this treatment, there are over 35 thousand sites across the globe conducting research on this medicine.

Q: How many participants have been accepted for this trial's enrollment?

This clinical trial has concluded its recruitment period and is no longer searching for patients. It was first posted on October 1st, 2015 and the listing most recently updated on April 8th 2022. For those looking to participate in other trials, there are currently 758 medical studies recruiting <a href="https://www.withpower.com/clinical-trials/melanoma">melanoma</a> patients and 960 FLT PET related studies actively enrolling participants.

Phase < 1

Waitlist Available

Led By Yvonne Saenger, MD

Research Sponsored by Yvonne Saenger

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 2 years

Awards & highlights

MPAK Trial Summary

This trial will test whether two imaging techniques can detect changes in tumor size earlier for patients with metastatic melanoma receiving Pembrolizumab.

Eligible Conditions

Malignant Melanoma

MPAK Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Prevalence of lesion detection (sensitivity)

Secondary outcome measures

Change in RECIST Index

Change in patient response (expression levels)

Change in patient response (immunoscore)

+1 more

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183

21%

Fatigue

13%

Nausea

11%

Back pain

Shortness of Breath

Anemia

Abdominal pain

Diarrhea

Pneumonia

Kidney Injury and/or Infection

Dyspnea

Weight Loss

Malnutrition, Hypercalcemia and Weakness

Pneumothorax

Intractable pain, back pain, hip pain

Activated partial thromboplastin time prolonged

Pleural effusion

Atrial fibrillation with rapid ventricular response

Thrombocytopenia

Respiratory failure

Skin rash

colitis

100%

80%

60%

40%

20%

Study treatment Arm

Single Arm

MPAK Trial Design

1Treatment groups

Experimental Treatment

Group I: Pembrolizumab and FLTExperimental Treatment2 Interventions

Subjects will receive WB-DW MRI and FLT PET to assess disease burden after receiving pembrolizumab.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

2017

Completed Phase 2

~2010

FLT PET

2011

N/A

~10

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Yvonne SaengerLead Sponsor

1 Previous Clinical Trials

9 Total Patients Enrolled

Columbia UniversityLead Sponsor

1,433 Previous Clinical Trials

2,447,253 Total Patients Enrolled

Merck Sharp & Dohme LLCIndustry Sponsor

3,892 Previous Clinical Trials

5,060,665 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment presently seeking participants?

"Unfortunately, no more participants can be accepted for this trial. The study was published on October 1st 2015 and last updated April 8th 2022. For those seeking other trials, 758 studies involving melanoma are presently enrolling patients while 960 FLT PET experiments require volunteers."

Answered by AI

What medical applications normally require the use of FLT PET imaging?

"FLT PET is a commonly used therapy for various forms of cancer, such as melanoma and tumors with microsatellite instability high. Additionally, it can be utilized to measure the effects of chemotherapy on disease progression."

Answered by AI

Has there been any previous experimentation involving FLT PET?

"At present, the medical community is running 960 clinical trials to study FLT PET. Of those experiments, 122 are in Phase 3 of development. Although Houston, Texas has the most studies surrounding this treatment, there are over 35 thousand sites across the globe conducting research on this medicine."

Answered by AI

How many participants have been accepted for this trial's enrollment?

"This clinical trial has concluded its recruitment period and is no longer searching for patients. It was first posted on October 1st, 2015 and the listing most recently updated on April 8th 2022. For those looking to participate in other trials, there are currently 758 medical studies recruiting melanoma patients and 960 FLT PET related studies actively enrolling participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

MRI and PET to Assess Pembrolizumab Response

Yvonne Saenger 2015. "MRI and PET to Assess Pembrolizumab Response". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02591654.